Stock Report

Download full stock data and analysis for free Last Updated: 05-Sep-2026

Stock Rating

Is this stock worth it? Our ratings reveal the truth.

Wealth Insight New Issue

Serious stock insights. No fluff. No FOMO.

Recently Viewed

Clear All

Reneo Pharmaceuticals (RPHM) Key Ratios

Stock Card factsheet share-fund-plan-icon

$1.81

up-down-arrow $-15.49 (-89.54%)

As on 04-Oct-2024 18:32EDT

Market cap

info icon

$61 Mln

Revenue (TTM)

info icon

$1 Mln

P/E Ratio

info icon

--

P/B Ratio

info icon

0.8

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue -- -- -- -- --
EBIT 33.46 69.87 4.18 -164.17 --
Net Profit 36.38 72.55 3.25 -132.88 --
EPS -- -- -- -- --
Book Value -- -- -- -- --
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-23Dec-22
EBIT-Margin info -----4,286.57----
Net Margin info -2,644.59---3,851.29---2,644.59
Return on equity info -66.09---68.33-82.07-40.51
Return on Capital info -53.83-----81.03-40.27
Return on Assets info -49.33---46.76-71.78-38.19
Debt to Equity (x) info ----0.000.010.01

Profitability

View Detailed Peer Comparison

ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
--
-81.03
-40.27
-40.21
-53.23
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

-68.33

Lower than Peers by 27.93

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
-68.33
-82.07
-40.51
-75.68
59.67
Peer Median
-40.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

-46.76

Lower than Peers by 15.78

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
-46.76
-71.78
-38.19
-38.01
-48.22
Peer Median
-30.98
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

-4,286.57

Lower than Peers by 4,202.95

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
-4,286.57
--
--
--
--
Peer Median
-83.62
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

-3,851.29

Lower than Peers by 3,758.62

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
-3,851.29
--
-2,644.59
--
--
Peer Median
-92.67
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

-0.03

Lower than Peers by 0.03

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
-0.03
--
--
--
--
Peer Median
0.00
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

EBIT Growth

4.18

Higher than Peers by 4.98

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
4.18
-51.79
-36.34
-103.65
-26.36
Peer Median
-0.80
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

3.25

Higher than Peers by 10.55

Year on year growth in profit after tax

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
3.25
-54.58
-25.88
-104.32
-56.52
Peer Median
-7.30
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

--

--

Total debt / Net worth

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
--
0.01
0.01
--
-2.20
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.00

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
0.00
0.00
0.00
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

57.86

Higher than Peers by 52.05

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
57.86
5.87
14.93
24.79
12.01
Peer Median
5.81
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

57.86

Higher than Peers by 52.16

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
57.86
--
--
--
--
Peer Median
5.70
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

-26.82

Lower than Peers by 24.74

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
-26.82
--
-28.68
-829.54
--
Peer Median
-2.09
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

--

--

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
--
--
--
--
--
Peer Median
19.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.01

Lower than Peers by 0.05

Sales / Average Total Assets

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
0.01
--
--
--
--
Peer Median
0.06
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
--
3,690.76
1,351.56
10,701.83
7,156.93
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Book Value

0.79

Lower than Peers by 4.39

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
0.79
--
--
--
--
Peer Median
5.18
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

0.16

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
0.16
1.24
1.85
3.71
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

61

Lower than Peers by 85

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-23
Dec-22
Dec-21
Dec-20
Reneo Pharmaceuticals (RPHM)
61
--
--
--
--
Peer Median
146
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...